Activated protein-C (APC) resistance, a poor anticoagulant response to APC due to a mutation of the factor V gene (factor V Leiden, FVL), has recently been reported to be the most common hereditary coagulation disorder associated with familial deep venous thrombosis. However, all data have been derived from investigation of Western populations. Therefore we investigated the prevalence of low APC ratios (APC resistance) and FVL in Japanese patients suffering from ischemic stroke (n = 106) and neurological diseases without vascular involvement (n = 37). We conclude that the prevalence of low APC ratios (APC resistance) and FVL is very low in Japanese ischemic stroke patients, and the low APC ratio found in 2 of 143 subjects might be attributable to coexistent antiphospholipid antibodies and/or protein-S deficiency rather than to FVL. Our results suggest the existence of racial differences in the frequency and cause of APC resistance.

Keywords:
Activated protein C resistance, Factor V Leiden, Genetics, Japanese, Ischemic stroke
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.